Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase
Authors' conclusion
CV/TE event incidence during pegloticase treatment was similar to the general gout population (31.7 events/1000 person-years).
Study context
- Population
- Patients with uncontrolled gout in two phase 3 trials, the MIRROR open-label trial and the MIRROR RCT4 trials pooled
- Participants
- 328 vs 244
- Comparison
- Pegloticase vs On-label
- Pegloticasen = 328
- On-label (biweekly)n = 244
- Outcome
- Treatment-emergent cardiovascular (CV)/thromboembolic (TE) events
- Follow-up
- First 24 weeks of therapy
Methodological detailspooled data
- Pooled data
Pooled result
As reported in the abstract
≥1 CV/TE event during pegloticase treatment
| Group | Value | Incidence rate |
|---|---|---|
| Pegloticase | 1.5% | |
| On-label (biweekly) | 1.2% | 35.4 events/1000 person-years |
Value
Pegloticase1.5%
On-label (biweekly)1.2%
Incidence rate
Pegloticase— not stated in the abstract
On-label (biweekly)35.4 events/1000 person-years
Original publication
Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. Rheumatology (Oxford). Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →